Reading the Research: WOMAC Pain Scores, Walking Distance, and What the Cartigenix HP Data Tells Clinicians

Image Credit: Envato

When clinicians evaluate published research behind a joint health supplement, they look at validated instruments, findings that hold across study designs, and outcome measures they can apply to clinical decision-making. 

The Cartigenix HP® with RestorCel™ research profile from Calroy Health Sciences is built on three such instruments across three published human studies: WOMAC pain scores, six-minute walk test results, and cartilage regeneration biomarkers. Each measure captures a distinct dimension of joint health, and together they give clinicians a framework for evaluating the full scope of the findings.

What the WOMAC Pain Scale Measures and Why It Matters

The WOMAC Pain scale (Western Ontario and McMaster Universities Osteoarthritis Index) is one of the most widely used validated instruments in joint health clinical research. It captures participant-reported joint discomfort across standardized domains covering pain, stiffness, and physical function during everyday activities, producing a composite score that enables comparison across studies and populations. Because WOMAC uses fixed, validated questions rather than ad hoc ratings, its standardization gives it clinical utility.

Across all three published human studies on Cartigenix HP® with RestorCel™, participants showed an average 67% reduction in WOMAC pain scores at 90 days.*† In the Vaidya 2025 randomized, placebo-controlled trial specifically, participants showed a 64% average reduction over that same period, with improvements beginning to appear in many participants as early as 15 days. The Desai 2022 prospective study (n=1,236) documented a 72.5% improvement in WOMAC pain scores, and the Desai 2024 observational study (n=394) averaged a 75% improvement.

For clinicians, the consistency across study designs anchors the finding. A 64–75% range of WOMAC score reduction across three populations and three different study designs suggests the outcome holds across conditions rather than reflecting a single favorable sample.

The Six-Minute Walk Test: Adding a Functional Layer to the Data

The six-minute walk test records total distance covered during a six-minute walking period under standardized conditions. It is an objective measure of real-world mobility that stands independently from self-report.

In the Vaidya 2025 randomized, placebo-controlled study, participants showed a 50% average improvement in walking distance at 90 days.*† That gain was measured against a placebo control group in a 62-person study population.

“What stands out about the Vaidya study isn’t just the pain reduction or the walking distance. Those are meaningful patient-reported metrics. But the biomarker data is the real shift. PIIANP and PIICP increasing in a placebo-controlled setting tells us something was happening at the tissue level, not just in how participants felt. That’s the distinction practitioners have been waiting for in this category,” says Tom Bayne, DC, educator with Calroy Health Sciences.

The two-measure pairing within the Vaidya 2025 trial is clinically useful because WOMAC and the six-minute walk test capture different aspects of joint health: one is self-reported, the other is objective and functional. 

Cartilage Regeneration Biomarkers and What the Full Research Profile Gives Clinicians

The Vaidya 2025 trial went beyond comfort and mobility measures to include objective tissue-level data. Investigators tracked PIIANP and PIICP, validated biomarkers of type II procollagen synthesis, the primary structural protein of the cartilage matrix. An increase in these biomarkers indicates that cartilage matrix regeneration was occurring at the tissue level, providing a biological signal that the intervention was influencing structural cartilage alongside the comfort and mobility outcomes participants reported.*

The study also tracked CTX-II and COMP, which are markers associated with cartilage degeneration. Both showed significant decreases over the 90-day study period.*†

These biomarkers are research instruments. Their value in the Vaidya 2025 dataset is that they provide a third, impartial measurement layer alongside participant-reported outcomes and functional performance data. For clinicians evaluating joint health supplementation, the progression from large-scale observational data to a placebo-controlled trial with tissue-level biomarker findings gives practitioners specific, nameable results to reference when evaluating options in this category.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores, along with quality of life measures (Desai 2022).

FAQs 

Question: What is the WOMAC Pain scale and why is it used in joint health research? 

Answer: The WOMAC Pain Scale (Western Ontario and McMaster Universities Osteoarthritis Index) is a validated clinical instrument that captures participant-reported joint discomfort across standardized domains, including pain, stiffness, and physical function during everyday activities. Its fixed question format enables comparison across studies and populations, which gives it utility in evaluating joint health interventions.

Question: What does the six-minute walk test measure in joint health studies? 

Answer: The six-minute walk test records total distance covered during a six-minute walking period under standardized conditions. It provides an objective, functional indicator of real-world mobility capacity that is independent of participant-reported comfort, making it a useful complement to self-reported pain scales when assessing the practical effects of a joint health intervention.

Question: What are cartilage regeneration biomarkers, and how are they used in research? 

Answer: Cartilage regeneration biomarkers are measurable biological signals that indicate activity at the structural level of cartilage tissue. In joint health research, markers such as PIIANP and PIICP reflect type II procollagen synthesis, while CTX-II and COMP are associated with cartilage degeneration. These are research instruments and are not typically ordered in routine clinical practice.

Question: Why does it matter that both WOMAC scores and walk test results were measured in the same study? 

Answer: WOMAC reflects how participants describe their joint comfort, while the six-minute walk test reflects what they can physically do. Movement in both measures within the same study population provides a more complete picture of the intervention’s effects.

Question: What is the significance of cartilage degeneration biomarkers decreasing alongside regeneration biomarkers increasing? 

Answer: Tracking both regeneration markers (PIIANP, PIICP) and degeneration markers (CTX-II, COMP) in the same study provides two complementary signals. An increase in regeneration markers alongside a decrease in degeneration markers suggests activity at the tissue level in both directions, supporting structural integrity while reducing breakdown.